Tumor necrosis factor (TNF) blockers, comprising etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab, have been well-recognized as one of the most promising therapies for various inflammatory diseases, including ankylosing spondylitis. The gene discussed is TNF; the disease is ankylosing spondylitis.